Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06010901 |
TitleA Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. | 阶段
第 1 阶段
|
Date Added 2023-08-25 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Anlotinib hydrochloride capsules, Penpulimab Injection, TQB2618 injection |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06011772 |
TitleA Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | 阶段
早期阶段 1
|
Date Added 2023-08-25 |
地点
New York, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
暂停
|
药物
fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06013111 |
TitleAn Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2023-08-28 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06099821 |
TitleKN046联合瑞戈非尼或阿帕替尼治疗对PD-1/PD-L1阻断剂耐药的MSI-H消化系统癌症 | 阶段
第二阶段
|
Date Added 2023-10-25 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
apatinib, KN046, Regorafenib |
标签
MSI-H/ MMRd
|
| NCT ID NCT06102902 |
TitleTesting the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC | 阶段
第 1 阶段
|
Date Added 2023-10-26 |
地点
California, United States
Kansas, United States Ohio, United States Oklahoma, United States Texas, United States Virginia, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
BET Bromodomain Inhibitor ZEN-3694, encorafenib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06105021 |
TitlePhase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | 阶段
Phase 1, Phase 2
|
Date Added 2023-10-27 |
地点
California, United States
Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
AFNT-211 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03223779 |
TitleTAS-102 加放射疗法治疗结直肠癌肝转移患者肝脏的研究 | 阶段
第 1 阶段
|
Date Added 2017-07-21 |
地点
Massachusetts, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06120127 |
TitlePostoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence | 阶段
第二阶段
|
Date Added 2023-11-07 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Chemotherapy, PD-1 antibody |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06253520 |
TitleAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | 阶段
第 1 阶段
|
Date Added 2024-02-12 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Aldesleukin, Cyclophosphamide, Fludarabine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06302062 |
TitlePhase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2024-03-08 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell |
标签
MSI-H/ MMRd, MSS/ MMRp
|
